Form 8-K
8-K — IMMUNIC, INC.
Accession: 0001493152-26-051543
Filed: 2026-11-13
Period: 2026-11-13
CIK: 0001280776
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — form8-k.htm (Primary)
EX-99.1 (ex99-1.htm)
GRAPHIC (ex99-1_001.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: form8-k.htm · Sequence: 1
false
0001280776
0001280776
2026-11-13
2026-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 13, 2026
IMMUNIC,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
001-36201
56-2358443
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS
Employer
Identification
No.)
1200
Avenue of the Americas, Suite 200
New
York, NY
10036
USA
(Address
of principal executive offices)
Registrant’s
telephone number, including area code: (332) 255-9818
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of exchange on which registered
Common
Stock, par value $0.0001
IMUX
The
Nasdaq Stock Market LLC
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐
Item
2.02. Results of Operations and Financial Condition
On
November 13, 2026, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit
99.1, announcing the Company’s financial results for the quarter ended September 30, 2026, and providing a corporate update (the
“Earnings Release”).
The
information contained in Item 2.02 of this Current Report on Form 8-K, including the Earnings Release, shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section
or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated
by reference into any of the Company’s filings with the Securities and Exchange Commission, except as shall be expressly set forth
by specific reference in any such filing.
Item
9.01. Financial Statements and Exhibits
Exhibit
Description
99.1
Press Release dated November 13, 2026.
104
Cover
Page to this Current Report on Form 8-K in Inline XBRL.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, hereunto duly authorized.
Dated:
November 13, 2026
Immunic, Inc.
By:
/s/
Erik Lundgren
Erik
Lundgren
Chief
Executive Officer
EX-99.1
EX-99.1
Filename: ex99-1.htm · Sequence: 2
Exhibit
99.1
Immunic,
Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
–
Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data
Expected in December 2026 –
–
Initiation of Phase 3 PROTECT-MS Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Ongoing, with First-Patient-Enrolled
Expected in the First Half of 2027 –
–
Executive Leadership Team Further Strengthened with Appointments of Chief Data and Digital Officer and Chief People Officer to Support
Regulatory and Commercial Readiness –
NEW
YORK, November 13, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development
of novel oral therapies for neurologic diseases, today reported financial results for the third quarter ended September 30, 2026, and
provided a corporate update.
“As
we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is
entering one of the most important periods in its history,” said Erik Lundgren, Chief Executive Officer of Immunic. “We are
evolving from a science-driven biotechnology company into a fully integrated commercial organization, with a key focus on understanding
and addressing the needs of people living with MS. We believe vidofludimus calcium has the potential to address mechanisms associated
with both the neurodegenerative and inflammatory drivers of the disease, which, if confirmed in our Phase 3 trials, could offer a differentiated
treatment option in MS. Subject to positive ENSURE results, we are preparing for a potential New Drug Application (NDA) submission in
relapsing MS, while we continue to advance our Phase 3 program in progressive MS.”
“We
were fortunate to present exciting data in four posters at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting, which added
complementary clinical and mechanistic evidence supporting the potential of vidofludimus calcium to address existing unmet needs in MS,”
added Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic. “Further, our Phase 3 ENSURE trials in relapsing MS continue
to be on track to report top-line data in December 2026. Our teams remain focused on this readout and readiness for a potential NDA submission
should the results be positive. In parallel, the Phase 2 CALLIPER data along with the insights shared by leading MS experts at our two
recent R&D Days support the rational for our Phase 3 PROTECT-MS trial in progressive MS, with initiation ongoing and first-patient-enrolled
expected in the first half of 2027.”
Third
Quarter 2026 and Subsequent Highlights
● Ongoing
Phase 3 ENSURE Relapsing MS Program: Continued to execute the fully enrolled twin Phase
3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS, which randomized
1,121 and 1,100 patients, respectively, at more than 100 sites in 15 countries.
● Preparation
of Phase 3 Progressive MS Program: Continued initiation activities for the Phase 3 PROTECT-MS
trial in progressive MS, informed by the Phase 2 CALLIPER trial data.
● Hosted
Virtual Progressive MS R&D Day: On November 5, 2026, hosted a virtual R&D
day focused on progressive MS. Jiwon Oh, M.D., Ph.D., FRCPC, Division of Neurology, University
of Toronto, and Maria Pia Sormani, Ph.D., University
of Genoa, Italy, joined Immunic’s management team to discuss the key unmet needs
in progressive MS and the persistent needs for innovative
approaches to the development of therapies that target novel mechanisms associated with neurodegeneration
and MS progression. The event highlighted the potential expansion opportunity for
vidofludimus calcium in progressive MS, including the clinical and scientific rationale supporting
Immunic’s plans to initiate a Phase 3 progressive MS trial. A replay is available on
the “Events and Presentations” section of Immunic’s website.
● New
Data Presented at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting: Presented
new clinical, biomarker and preclinical data for vidofludimus calcium across four poster
presentations at MSToronto2026, held October 21-23, 2026, in Toronto. Highlights included:
○ New
analyses of the Phase 2 CALLIPER trial in progressive MS showed that the favorable trends
on disability outcomes observed during the double-blind main treatment period appeared to
be maintained during the open-label extension (OLE) phase among participants who continued
vidofludimus calcium treatment. Because the OLE phase is not placebo-controlled and includes
only participants who elected to continue treatment, these results should be interpreted
with caution. Only 6.5% of patients discontinued through the January 27, 2026 data cutoff,
with a safety and tolerability profile that appeared consistent with that observed in the
double-blind period.
○ New
preclinical findings suggest that vidofludimus calcium promoted neuronal survival under apoptotic
stress conditions, an effect requiring Nurr1. Under these in vitro experimental conditions,
this Nurr-1 dependent pro-survival effect was not observed with teriflunomide, providing
preclinical evidence suggesting that it involves mechanisms beyond DHODH inhibition. The
clinical relevance of these findings has not been established.
○ An
exploratory CALLIPER analysis found that vidofludimus calcium reduced Epstein-Barr virus
(EBV)-specific T-cell receptor sequence matches versus placebo-treated patients, and, in
a post-hoc analysis across all patients, reductions in EBV-specific matches were associated
with improved Symbol Digit Modalities Test (SDMT) scores.
○ In
a post-hoc analysis applying two proposed novel statistical methods that integrate disability
worsening and improvement into a single statistical measure, progressive MS patients in CALLIPER
treated with vidofludimus calcium appeared more likely to have positive disability outcomes
compared to placebo. These methods have not been validated or accepted by regulatory authorities.
● Hosted
Virtual Relapsing MS R&D Day: On September 9, 2026, hosted a virtual R&D day
focused on relapsing MS, at which management discussed the potential of vidofludimus
calcium to address mechanisms associated with both neurodegenerative and inflammatory drivers
of MS and shared insights into how its differentiated approach could add to the evolving
treatment landscape in relapsing MS. MS experts Amit Bar-Or, M.D., FRCPC, Perelman School
of Medicine, University of Pennsylvania, and Stephen Krieger, M.D., FAAN, Icahn School of
Medicine, The Mount Sinai Hospital, provided expert perspectives on the MS patient journey,
current treatment paradigms and unmet medical needs. A replay is available on the “Events
and Presentations” section of Immunic’s website.
● Expansion
of Executive Leadership Team and Board of Directors:
○ Appointed
Jaa Roberson as Chief People Officer, effective October 19, 2026. In this newly created executive
role, Ms. Roberson leads Immunic’s global talent and organizational strategy as the
company prepares for the ENSURE read-out and potential commercialization. Ms. Roberson brings
more than two decades of human resources experience, most recently as Chief People Officer
at Day One Biopharmaceuticals, and earlier, at Genentech supporting commercial franchises,
including Ocrevus® for MS.
○ Appointed
Chitrang Davé, M.B.A., as Chief Data and Digital Officer, effective September 1, 2026.
In this newly created C-suite role, Mr. Davé leads Immunic’s enterprise-wide
data, analytics, AI and digital strategy in support of NDA and commercial readiness. Mr.
Davé brings more than 25 years of data and analytics leadership experience across
regulated life sciences environments, most recently as Head of Enterprise Data, AI &
Advanced Analytics at Avidity Biosciences, and previously in senior roles at Edwards Lifesciences
and Medtronic.
○ Appointed
Elena Ridloff, CFA, to the Board of Directors, effective August 6, 2026. Ms. Ridloff brings
more than 20 years of leadership experience in finance, corporate development, investor relations,
and capital markets across the biopharmaceutical industry. She currently serves as Chief
Financial Officer and Chief Business Officer at Sionna Therapeutics.
Anticipated
Clinical Milestones
● Vidofludimus
Calcium in Relapsing MS: Top-line data from the twin Phase 3 ENSURE-1 and ENSURE-2 trials
remains on track and is expected to be available in December 2026. If positive, Immunic plans
to submit an NDA in the United States in mid-2027, with a targeted potential regulatory approval
date in 2028.
● Vidofludimus
Calcium in Progressive MS: The initiation of the Phase 3 PROTECT-MS trial in progressive
MS is ongoing, with first-patient-enrolled expected in the first half of 2027.
● IMU-381:
The IMU-381 program, selected to leverage the Nurr1 platform for neurologic and autoimmune
diseases, continues to be in preclinical testing with lead candidate identification ongoing.
Financial
and Operating Results
Total
Operating Expenses for the three and nine months ended September 30, 2026 were $43.4 million and $111.9 million, respectively. Included
in these results are $13.9 million and $25.2 million, respectively, of non-cash charges, primarily related to stock compensation expense.
Research
and Development (R&D) Expenses were $23.9 million for the three months ended September 30, 2026, as compared to $20.0 million
for the three months ended September 30, 2025. The $3.9 million increase reflects (i) a $1.9 million increase in personnel expenses,
$0.6 million of which was related to non-cash stock compensation, (ii) a $1.4 million increase for vidofludimus calcium drug supply,
(iii) a $2.9 million increase for NDA readiness activities, (iv) a $0.3 million increase due to drug-drug interaction studies in support
of a potential NDA filing and (v) a $0.2 million increase related to costs across numerous categories, partially offset by (vi) a $1.8
million decrease related to the ENSURE clinical trials and (vii) a $1.0 million decrease related to the CALLIPER clinical trial.
For
the nine months ended September 30, 2026, R&D expenses were $75.5 million, as compared to $62.9 million for the nine months ended
September 30, 2025. The $12.6 million increase reflects (i) a $7.4 million increase in personnel expenses, $4.4 million of which was
related to non-cash stock compensation, (ii) a $4.5 million increase for vidofludimus calcium drug supply, (iii) a $4.1 million increase
for NDA readiness activities, (iv) a $3.9 million increase due to drug-drug interaction studies in support of a potential NDA filing
and (v) a $1.7 million increase related to costs across numerous categories, partially offset by (vi) a $5.2 million decrease related
to the ENSURE clinical trials and (vii) a $3.8 million decrease related to the CALLIPER clinical trial.
General
and Administrative (G&A) Expenses were $19.4 million for the three months ended September 30, 2026, as compared to $6.0 million
for the same period ended September 30, 2025. The $13.4 million increase was due to (i) an $11.0 million increase related to personnel
expenses, of which $9.7 million was related to non-cash stock compensation primarily related to a separation agreement, (ii) a $1.3 million
increase in legal and consultancy expenses, (iii) a $0.6 million increase in pre-commercial marketing expenses and (iv) a $0.5 million
increase in related costs across numerous categories.
For
the nine months ended September 30, 2026, G&A expenses were $36.4 million, as compared to $17.0 million for the same period ended
September 30, 2025. The $19.4 million increase was due to (i) a $15.2 million increase related to personnel expenses, of which $13.2
million was related to non-cash stock compensation primarily related to a separation agreement, (ii) a $2.3 million increase in legal
and consultancy expenses, (iii) a $1.2 million increase in pre-commercial marketing expenses and (iv) a $0.7 million increase in related
costs across numerous categories.
Interest
Income was $1.1 million for the three months ended September 30, 2026, as compared to $0.4 million for the three months ended September
30, 2025. The $0.7 million increase was due to a higher average cash balance as a result of the February 2026 Private Placement.
For
the nine months ended September 30, 2026, interest income was $3.1 million, as compared to $0.8 million for the same period ended September
30, 2025. The $2.3 million increase was due to a higher average cash balance as a result of the February 2026 Private Placement.
Other
Income (Expense) was ($0.03 million) for the three months ended September 30, 2026, as compared to ($0.01 million) for the same period
ended September 30, 2025.
For
the nine months ended September 30, 2026, Other Income (Expense) was ($0.2 million), as compared to $1.2 million for the same period
ended September 30, 2025. The $1.4 million decrease was primarily attributable to (i) $1.0 million of grant income from the German Federal
Ministry of Finance recognized in the first quarter of 2025 and no grant income in 2026 and (ii) a $0.4 million decrease across various
categories.
Net
Loss for the three months ended September 30, 2026, was approximately $42.3 million, or $0.99 per basic and diluted share, based
on 42,797,370 weighted-average common shares outstanding, compared to a net loss of approximately $25.6 million, or $1.32 per basic and
diluted share, based on 19,389,776 weighted-average common shares outstanding for the same period ended September 30, 2025.
Net
loss for the nine months ended September 30, 2026, was approximately $109.0 million, or $2.83 per basic and diluted share, based on 38,508,964
weighted-average common shares outstanding, compared to a net loss of approximately $77.9 million, or $5.45 per basic and diluted share,
based on 14,281,149 weighted-average common shares outstanding for the same period ended September 30, 2025.
Cash
and Cash Equivalents as of September 30, 2026 were $132.0 million. Based on its current operating plan, Immunic expects that these
funds will be sufficient to fund its operations into late 2027.
About
Immunic, Inc.
Immunic,
Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases.
The company’s lead investigational asset, vidofludimus calcium (IMU-838), is currently
being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available in December 2026.
Initiation of an additional Phase 3 clinical trial in progressive multiple sclerosis is ongoing, with first-patient-enrolled expected
in the first half of 2027. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1
(Nurr1) activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase
(DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building
a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com.
Vidofludimus
calcium (IMU-838) is an investigational medicinal product that has not been approved or authorized by the U.S. Food and Drug Administration
(FDA), the European Medicines Agency (EMA), or any other regulatory authority for any indication in any jurisdiction. Its safety and
efficacy have not been established. Any clinical, biomarker, or preclinical findings described reflect investigational data and are not
intended to suggest that vidofludimus calcium is safe or effective for any use.
Cautionary
Statement Regarding Forward-Looking Statements
This
press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts,
included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses,
sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of
management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the nature,
strategy and focus of the company; the development and commercial potential of Immunic’s product candidates, including their potential
to safely and effectively target diseases; preclinical and clinical data for Immunic’s development programs; the expected timing
and results of the Phase 3 ENSURE trials; the timing of a Phase 3 trial of vidofludimus calcium in progressive multiple sclerosis; the
timing of potential NDA submission and regulatory approval; expectations regarding the capitalization, resources and ownership structure
of the company; the expected sufficiency of Immunic’s cash and cash equivalents; and the executive and board structure of the company.
Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking
statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s
current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those
projected in the forward-looking statements as a result of many factors, including, without limitation, the risk that top-line results
from the ENSURE-1 and ENSURE-2 trials may be delayed, negative, or fail to meet their primary or secondary endpoints; the risk that results
of earlier, post-hoc, exploratory, open-label or preclinical analyses may not be predictive of, or confirmed in, subsequent controlled
clinical trials or accepted by regulatory authorities; the risk that the initiation, or first-patient enrollment in, of the Phase 3 progressive
MS trial, or the submission or approval of an NDA, may be delayed or may not occur; risks related to drug development and the regulatory
review process; the risk that Immunic’s cash and cash equivalents may be insufficient to fund operations for the period anticipated,
including due to changes to its operating plan, and Immunic’s need to raise additional capital; increasing inflation, tariffs and
macroeconomic trends; impacts of the Ukraine – Russia conflict and the conflict in the Middle East on clinical trials; changes
to the size of the target markets for the company’s product candidates; the protection and market exclusivity provided by Immunic’s
intellectual property; and the impact of competitive products and technological changes. A further list and descriptions of these risks,
uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent
filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Copies of these filings are
available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the
date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances
that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken
based on any or all of the contents of this press release.
Contact
Information
Immunic,
Inc.
Jessica
Breu
Vice
President Investor Relations and Communications
+49
89 2080 477 09
jessica.breu@imux.com
US
IR Contact
LifeSci
Advisors
Joyce
Allaire
immunic@lifesciadvisors.com
US
Media Contact
Real
Chemistry
media@imux.com
Financials
Immunic,
Inc.
Condensed
Consolidated Balance Sheets
(In
thousands, except share and per share amounts)
(Unaudited)
September 30,
2026
December 31,
2025
(Unaudited)
Assets
Current assets:
Cash and cash equivalents
$ 131,963
$ 15,483
Other current assets and prepaid expenses
3,124
7,386
Total current assets
135,087
22,869
Property and equipment, net
832
608
Right-of-use assets, net
504
575
Total assets
$ 136,423
$ 24,052
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$ 10,120
$ 10,138
Accrued expenses
20,058
18,645
Other current liabilities
1,372
1,835
Total current liabilities
31,550
30,618
Long-term liabilities
Other long term liabilities
400
107
Total long-term liabilities
400
107
Total liabilities
31,950
30,725
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of September 30, 2026 and December 31, 2025
—
—
Common stock, $0.0001 par value; 500,000,000 authorized as of September 30, 2026 and December 31, 2025, and 15,880,822 and 12,038,263 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively
1
1
Additional paid-in capital
819,290
599,249
Accumulated other comprehensive income
2,749
2,648
Accumulated deficit
(717,567 )
(608,571 )
Total stockholders’ equity
104,473
(6,673 )
Total liabilities and stockholders’ equity
$ 136,423
$ 24,052
Immunic,
Inc.
Condensed
Consolidated Statements of Operations
(In
thousands, except share and per share amounts)
(Unaudited)
Three Months
Ended September 30,
Nine Months
Ended September 30,
2026
2025
2026
2025
Operating expenses:
Research and development
$ 23,948
$ 20,012
$ 75,505
$ 62,914
General and administrative
19,421
5,981
36,426
16,987
Total operating expenses
43,369
25,993
111,931
79,901
Loss from operations
(43,369 )
(25,993 )
(111,931 )
(79,901 )
Other income (expense):
Interest income
1,093
419
3,139
843
Other income (expense), net
(33 )
(5 )
(204 )
1,186
Total other income
1,060
414
2,935
2,029
Net loss
$ (42,309 )
$ (25,579 )
$ (108,996 )
$ (77,872 )
Net loss per share, basic and diluted
$ (0.99 )
$ (1.32 )
$ (2.83 )
$ (5.45 )
Weighted-average common shares outstanding, basic and diluted
42,797,370
19,389,776
38,508,964
14,281,149
GRAPHIC
GRAPHIC
Filename: ex99-1_001.jpg · Sequence: 3
Binary file (3195 bytes)
Download ex99-1_001.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.3
Cover
Nov. 13, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Nov. 13, 2026
Entity File Number
001-36201
Entity Registrant Name
IMMUNIC,
INC.
Entity Central Index Key
0001280776
Entity Tax Identification Number
56-2358443
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
1200
Avenue of the Americas
Entity Address, Address Line Two
Suite 200
Entity Address, City or Town
New
York
Entity Address, State or Province
NY
Entity Address, Country
US
Entity Address, Postal Zip Code
10036
City Area Code
(332)
Local Phone Number
255-9818
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common
Stock, par value $0.0001
Trading Symbol
IMUX
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
ISO 3166-1 alpha-2 country code.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCountry
Namespace Prefix:
dei_
Data Type:
dei:countryCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration